

[Primaquine](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

ATC codes: [P01BA03](#)

EMLc

Indication

Malaria due to Plasmodium ovale ICD11 code: [1F43](#)

INN

Primaquine

Medicine type

Chemical agent

List type

Core

Additional notes

For use to reduce the transmission of Plasmodium falciparum and for radical cure of Plasmodium vivax and Plasmodium ovale infections.

Formulations

Oral > Solid > tablet: 7.5 mg (as phosphate) ; 15 mg (as phosphate)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Primaquine](#)

DrugBank

[Primaquine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to update the footnote with the listing for primaquine to specify use only for reducing the transmission of Plasmodium falciparum and to achieve radical cure of Plasmodium vivax and Plasmodium ovale infections.